These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20948761)

  • 1. HER2 status and breast cancer therapy: recent advances.
    Tripathy D
    F1000 Med Rep; 2009 Mar; 1():. PubMed ID: 20948761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-targeting estrogen receptor and HER2 pathways in breast cancer.
    Mehta A; Tripathy D
    Breast; 2014 Feb; 23(1):2-9. PubMed ID: 24176518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer.
    Kim M; Agarwal S; Tripathy D
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):27-33. PubMed ID: 24335887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
    Marra A; Chandarlapaty S; Modi S
    Nat Rev Clin Oncol; 2024 Mar; 21(3):185-202. PubMed ID: 38191924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A; Baselga J
    Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
    Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
    Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
    Yang Z; Barnes CJ; Kumar R
    Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
    Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
    Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
    Duchnowska R; Loibl S; Jassem J
    Cancer Treat Rev; 2018 Jun; 67():71-77. PubMed ID: 29772459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
    Ahmed S; Sami A; Xiang J
    Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 targeted therapy in breast cancer...beyond Herceptin.
    Pal SK; Pegram M
    Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.
    Kourie HR; El Rassy E; Clatot F; de Azambuja E; Lambertini M
    Onco Targets Ther; 2017; 10():3363-3372. PubMed ID: 28744140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
    Vazquez-Martin A; Colomer R; Brunet J; Lupu R; Menendez JA
    Cell Prolif; 2008 Feb; 41(1):59-85. PubMed ID: 18211286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HER2: recent developments and future directions for breast cancer patients.
    Wang SC; Zhang L; Hortobagyi GN; Hung MC
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going.
    Schettini F; Buono G; Cardalesi C; Desideri I; De Placido S; Del Mastro L
    Cancer Treat Rev; 2016 May; 46():20-6. PubMed ID: 27057657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer.
    Singla H; Munshi A; Banipal RPS; Kumar V
    Curr Cancer Drug Targets; 2018; 18(4):306-327. PubMed ID: 28669349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.